InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,837.25
(
0.07%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Telephonics

Send PM Follow Ignore
Followers 3
Posts 1277
Boards Moderated 1
Alias Born 04/02/2003

Telephonics

Re: None

Monday, 02/26/2007 9:32:33 AM

Monday, February 26, 2007 9:32:33 AM

Post# of 4764

Merck KGaA: Stimuvax Cancer Vaccine Phase III Study Begins


Darmstadt, Germany, February 26, 2007 – Merck KGaA today announced that the
first patient has been enrolled in its global Phase III clinical study,
START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the
efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential
treatment for patients with unresectable stage III non-small cell lung
cancer (NSCLC).

The complete news release can be downloaded at the following link:
http://me.merck.de/n/03FA0206AF8505B6C125728E003B81A5/$FILE/Stimuv-e.pdf
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up